CBLN1 and COVID-19: Indeed, these drugs have been shown to lower Cer concentration, hindering SARS-CoV-2 entry into cells and reducing hyperinflammation and pro-inflammatory cytokines (e.g., IL-6), which are considered risk factors for severe disease progression (such as hypertension, obesity, and thromboembolic complications), as well as the incidence of intubation and mortality in COVID-19 [96,97].